Search Filters
Specialties
Regenerative Medicine
Clear All
Search
Specialties
Regenerative Medicine
52 results found in 1ms
Questions to ask before a ChondroFiller injection
avatar
Miss Sophie Harris
24/8/2026
Questions to ask before a ChondroFiller injection
ChondroFiller is a Type I collagen hydrogel injected into the joint where it recruits the patient's own progenitor cells to repair cartilage over months rather than days. Specific suitability criteria apply; questions a patient asks beforehand substantially influence whether expectations align with realistic outcomes.ChondroFiller is a Type I collagen hydrogel injected into the joint where it recruits the patient's own progenitor cells to repair cartilage over months rather than days. Specific suitability criteria apply; questions a patient asks beforehand substantially influence whether expectations align with realistic outcomes.
ChondroFiller repeat injections and long-term repair
avatar
Miss Sophie Harris
23/8/2026
ChondroFiller repeat injections and long-term repair
ChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.ChondroFiller recruits the patient's progenitor cells into a collagen scaffold that degrades over 12–18 months whilst repair tissue develops; 81% of hip patients achieved good or excellent outcomes at three to five years, but success depends heavily on whether osteoarthritis is early-stage or advanced.
ChondroFiller Injection Evidence Patients Should Weigh
avatar
Miss Sophie Harris
15/8/2026
ChondroFiller Injection Evidence Patients Should Weigh
Injected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.Injected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.
ChondroFiller™ durability compared with Arthrosamid
avatar
Miss Sophie Harris
12/8/2026
ChondroFiller™ durability compared with Arthrosamid
ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
Who qualifies for ChondroFiller injection
avatar
Miss Sophie Harris
11/8/2026
Who qualifies for ChondroFiller injection
ChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.ChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.
ChondroFiller injection versus cartilage surgery
avatar
Miss Sophie Harris
6/8/2026
ChondroFiller injection versus cartilage surgery
ChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.ChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.
What separates ChondroFiller from Liquid Cartilage
avatar
Miss Sophie Harris
5/8/2026
What separates ChondroFiller from Liquid Cartilage
ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.
Who qualifies for ChondroFiller Liquid Cartilage injection
avatar
Miss Sophie Harris
26/7/2026
Who qualifies for ChondroFiller Liquid Cartilage injection
ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
ChondroFiller injection costs in the UK and Europe
avatar
Miss Sophie Harris
25/7/2026
ChondroFiller injection costs in the UK and Europe
ChondroFiller costs £3,000–£8,000 in the UK, scaled by defect size, delivered as an ultrasound-guided outpatient injection with no surgery or anaesthetic.ChondroFiller costs £3,000–£8,000 in the UK, scaled by defect size, delivered as an ultrasound-guided outpatient injection with no surgery or anaesthetic.
What ChondroFiller's CE approval means for UK patients
avatar
Miss Sophie Harris
20/7/2026
What ChondroFiller's CE approval means for UK patients
ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
What the ChondroFiller evidence actually shows
avatar
Miss Sophie Harris
19/7/2026
What the ChondroFiller evidence actually shows
ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
52 results found in 1ms